ACXP - Acurx Pharmaceuticals, Inc.

2.32
-0.040   -1.724%

Share volume: 82,870
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$2.36
-0.04
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 26%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.52%
1 Month
-48.73%
3 Months
-16.55%
6 Months
-64.47%
1 Year
515.87%
2 Year
17.17%
Key data
Stock price
$2.32
P/E Ratio 
N/A
DAY RANGE
$2.23 - $2.38
EPS 
-$2.55
52 WEEK RANGE
$0.28 - $8.34
52 WEEK CHANGE
$499.48
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
2.855 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$185,355
AVERAGE 30 VOLUME 
$262,270
Company detail
CEO: David P. Luci
Region: US
Website: www.acurxpharma.com
Employees: 3
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria.

Recent news